Suven Life Sciences Ltd. Share Price & Stock Analysis

Suven Life Sciences Ltd. (BSE: 530239) is a Hyderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹7,951 Cr, it ranks #666 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 10 in Life Sciences Tools and Services. At ₹277.90 (as of 19 Nov 2026), the share price is 31.1% below its 52-week high of ₹403.35 and 123.9% above its 52-week low of ₹124.11. The share price is up 51.8% over one year and down 16.6% over three months.

Key Metrics

Current Price₹277.90
Market Cap₹7,951 Cr
BSE Code530239
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services
P/E RatioNot meaningful (loss)
Return on Equity-78.80%
Return on Assets-47.69%
52-Week Range₹124.11 – ₹403.35
1-Year Price Change+51.8%
3-Month Price Change-16.6%
Beta (1Y)0.84
Dividend Yield0.00%
HeadquartersHyderabad, Telangana
Websitewww.suven.com

Latest Quarterly Results — Q2 FY27

Revenue₹1 Cr
Net Profit₹-107 Cr
Net Margin-8911.7%
EPS (Basic)₹-3.77
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Suven Life Sciences Ltd. Quarterly Revenue and Profit Trend

Suven Life Sciences Ltd. reported revenue of ₹1 Cr in Q2 FY27, up 30.4% from ₹1 Cr in Q2 FY26 and down 66.4% from ₹4 Cr in Q1 FY27. It posted a net loss of ₹107 Cr for the quarter, against a net loss of ₹77 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1 Cr (Q2 FY26) to ₹4 Cr (Q1 FY27). The company reported a net loss in 7 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1 Cr−₹107 Cr−8911.7%
Q1 FY27₹4 Cr−₹128 Cr−3574.5%
Q4 FY26₹2 Cr−₹46 Cr−3000.0%
Q3 FY26₹3 Cr−₹102 Cr−3627.0%
Q2 FY26₹1 Cr−₹77 Cr−8403.3%
Q1 FY26₹2 Cr−₹52 Cr−2755.1%
Q4 FY25₹1 Cr−₹44 Cr−2989.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 65.47% of Suven Life Sciences Ltd.'s shares as of Sept 2026, against 67.36% in Dec 2025 (−1.89 percentage points). Delivery averaged 39.9% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).

About Suven Life Sciences Ltd.

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D

Products and Services

1. Research and Development Services-This segment provides a range of drug discovery and development support services to pharma and biotech companies. 2. Manufacturing (CRAMS)-This segment develops and produces bulk drugs and intermediates under contract manufacturing services. 3. Services (DDDSS)-This segment offers clinical trials, testing, and analysis services, as well as engages in the collaborative research projects. 4. Unallocated-0

Business Segments

1. Research and Development Services-100%

Suven Life Sciences Ltd. vs Peers — Life Sciences Tools and Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Indegene Ltd₹14,840 Cr40.213.94%₹1,122 Cr+26.1%
Suven Life Sciences Ltd.₹7,951 Crn/m-78.80%₹1 Cr+51.8%
Vimta Labs Ltd₹2,259 Cr29.518.55%₹112 Cr-26.8%
Tarsons Products Limited₹1,730 Cr114.92.26%₹124 Cr+25.7%
Brooks Laboratories Ltd.₹198 Cr7.922.28%₹19 Cr-34.2%
Bilcare Ltd.₹194 Cr108.3-5.21%——
Jeevan Scientific Technology Ltd₹176 Cr129.41.68%—+42.3%
Vivo Bio Tech Ltd.₹37 Crn/m-2.00%₹14 Cr-55.7%
Dr. Habeebbullal Life Sciences Ltd₹26 Crn/m-68.79%—-45.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Suven Life Sciences Ltd.?

Suven Life Sciences Ltd. is trading at ₹277.90, with a market capitalisation of ₹7,951 Cr.

Which sector does Suven Life Sciences Ltd. belong to?

Suven Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).

What are the key financial ratios of Suven Life Sciences Ltd.?

Suven Life Sciences Ltd. has a return on equity of -78.80%.

What is the stock symbol of Suven Life Sciences Ltd.?

Suven Life Sciences Ltd. is listed on the BSE under the scrip code 530239.

How has Suven Life Sciences Ltd.'s share price moved over the past year?

Suven Life Sciences Ltd.'s share price is up 51.8% over one year and down 16.6% over three months. Its 52-week range is ₹124.11 to ₹403.35.

What were Suven Life Sciences Ltd.'s latest quarterly results?

In Q2 FY27, Suven Life Sciences Ltd. reported revenue of ₹1 Cr and net profit of ₹-107 Cr, with basic EPS of ₹-3.77 (consolidated, parsed from the company's exchange filing).

How have Suven Life Sciences Ltd.'s revenue and profit changed over the past year?

Suven Life Sciences Ltd. reported revenue of ₹1 Cr in Q2 FY27, up 30.4% from ₹1 Cr in Q2 FY26 and down 66.4% from ₹4 Cr in Q1 FY27.

What is the promoter holding in Suven Life Sciences Ltd.?

Promoters held 65.47% of Suven Life Sciences Ltd.'s shares as of Sept 2026, against 67.36% in Dec 2025 (−1.89 percentage points).

More on FinBizNet

Data as of 19 Nov 2026. Descriptive market data only — not investment advice.